SCHEDULE 13G/A: Blue Owl Capital Holdings LP Discloses 4.32% Stake in Sagimet Biosciences Inc.

Blue Owl Capital Holdings LP has filed an amended Schedule 13G, reporting a beneficial ownership of 4.32% of Sagimet Biosciences Inc.'s Series A common stock as of December 31, 2024.

Summary

• Blue Owl Capital Holdings LP (the "Reporting Person") has filed an Amendment No. 1 to Schedule 13G regarding its beneficial ownership in Sagimet Biosciences Inc. (the "Issuer").
• The filing indicates that the Reporting Person beneficially owns 1,323,877 shares of Sagimet Biosciences Inc.'s Series A common stock, $0.0001 par value per share (CUSIP 786700104).
• This ownership represents 4.32% of the Issuer's Series A common stock outstanding as of December 31, 2024.
• The percentage is calculated based on 30,674,855 shares of Series A common stock outstanding as of November 8, 2025, as reported in the Issuer's Form 10-Q filed with the SEC on November 14, 2025.
• The Reporting Person certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of or with the effect of changing or influencing the control of the issuer.

Sentiment

Score: 5

Explanation: The document is a factual regulatory disclosure of beneficial ownership, providing neutral information without expressing positive or negative sentiment regarding company performance or prospects.

Positives

• The disclosure of a significant stake (4.32%) by an institutional investor like Blue Owl Capital Holdings LP may signal institutional confidence or interest in Sagimet Biosciences Inc.

Future Outlook

This Schedule 13G filing is a disclosure of current beneficial ownership and does not contain any forward-looking statements or guidance regarding the Issuer's future outlook.

Management Comments

• Karen Hager, Chief Compliance Officer of Blue Owl Capital Holdings LP, certified that the securities were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer.

Industry Context

This filing provides transparency into institutional ownership, a common practice in the financial industry. Such disclosures are crucial for investors to understand the composition of a company's shareholder base and the positions held by significant institutional players.

Stakeholder Impact

• Shareholders: Provides transparency regarding significant institutional holdings, which can influence market perception and trading activity.

Key Dates

Keywords

Sagimet Biosciences, Blue Owl Capital, Schedule 13G, beneficial ownership, common stock, institutional investor, SEC filing, ownership disclosure